PD-1 antibody

Catalog No. ABIN2665970

The Mouse Monoclonal anti-PD-1 antibody has been validated for FACS, WB and IHC. It is suitable to detect PD-1 in samples from Human.

Quick Overview for PD-1 antibody (ABIN2665970)

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This PD-1 antibody is un-conjugated

Application: Flow Cytometry (FACS), Western Blotting (WB), Immunohistochemistry (IHC)

Clone: EH12-2H7

Product Details anti-PD-1 Antibody

Brand: Ultra-LEAF™

Cross-Reactivity: Chimpanzee, Marmoset, Rhesus Monkey, Squirrel Monkey (Saimiri spec.), Cynomolgus

Purification: The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.

Sterility: 0.2 μm filtered

Endotoxin Level:

Endotoxin level is <0.01 EU/μg of the protein (<0.001 ng/μg of the protein) as determined by the LAL test.

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 1.0 mg/mL

Preservative: Azide free

Handling Advice: This Ultra-LEAF™ solution contains no preservative, handle under aseptic conditions

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for PD-1

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Alternative Name: CD279

Background: Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.

Pathways: Cancer Immune Checkpoints